Impact of glucagon-like peptide 1 receptor agonist liraglutide and dipeptidyl peptidase-4 inhibitor sitagliptin on bowel cleaning and gastrointestinal symptoms in type 2 diabetes

被引:14
作者
Tong, Yan [1 ]
Huang, Jian Qing [1 ]
Chen, Yang [1 ]
Tu, Mei [1 ]
Wang, Wei [1 ]
机构
[1] Fujian Med Univ, Longyan Affiliated Hosp 1, Longyan, Fujian, Peoples R China
关键词
liraglutide; sitagliptin; bowel preparation quality; gastrointestinal discomfort; gastrointestinal motility; DOSE POLYETHYLENE-GLYCOL; GLUCOSE; COLONOSCOPY; EXENATIDE; SUPERIOR; MOTILITY; TRANSIT;
D O I
10.3389/fphar.2023.1176206
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i) profoundly affect the gastrointestinal motor system, which may increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms. Hence, this observational study mainly aimed to assess the influence of GLP-1 RAs liraglutide and DPP-4i sitagliptin on bowel preparation in type 2 diabetes (T2DM). Method: This observational study consecutively enrolled T2DM scheduled for a colonoscopy. Participants were prospectively separated into the liraglutide group (n = 120), sitagliptin group (n = 120), and control group (n = 120) based on the current hypoglycemic regimen. 3L split-dose polyethylene glycol regimens were used for bowel preparation. Experienced gastrointestinal endoscopists conducted colonoscopies. Lawrance Bowel-Preparation Tolerability Questionnaire and Boston Bowel Preparation Scale (BBPS) were conducted to assess bowel cleaning quality, tolerability, and safety. Results: The incidence of inadequate bowel cleaning was 17.5% in the liraglutide group, 20.5% in the sitagliptin group, and 21.7% in the control group. The difference among the three groups was not statistically significant (p = 0.927). Meanwhile, there were no significant differences in the mean BBPS, cecal intubation time, and polyp-detecting rates among the three groups (all p > 0.0.05). Nausea, vomiting, and bloating scores were increased in the liraglutide group compared with the other two groups (p < 0.05), whereas most were mild or very mild. Subgroup analyses showed that the incidence of inadequate bowel cleaning in T2DM with diabetic peripheral neuropathy (DPN) was increased in the liraglutide group compared with the sitagliptin group (61.3% vs. 32.1%, p = 0.022) and control group (61.3% vs. 32.8%, p = 0.025). Conclusion: GLP-1RA liraglutide or DPP-4i sitagliptin did not significantly increase the incidence of inadequate bowel cleaning and gastrointestinal symptoms during bowel preparation. Liraglutide may increase the incidence of inadequate bowel preparation in patients with DPN. This study reveal that more attention and aggressive bowel preparation regimens should be given to the T2DM with DPN.
引用
收藏
页数:9
相关论文
共 50 条
[21]   Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes [J].
Bensignor, Megan O. ;
Wolf, Jack M. ;
Rudser, Kyle D. ;
Kelly, Aaron S. ;
Arslanian, Silva .
DIABETES OBESITY & METABOLISM, 2022, 24 (07) :1380-1384
[22]   The effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide 1 receptor agonists on cognitive functions in adults with type 2 diabetes mellitus: a systematic review and meta-analysis [J].
Jin, Yuxin ;
Zhao, Hang ;
Hou, Yilin ;
Song, Guangyao .
ACTA DIABETOLOGICA, 2020, 57 (10) :1129-1144
[23]   Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: A meta-analysis of randomized clinical trials [J].
Tran, Susan ;
Retnakaran, Ravi ;
Zinman, Bernard ;
Kramer, Caroline K. .
DIABETES OBESITY & METABOLISM, 2018, 20 :68-76
[24]   Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)? [J].
Doggrell, Sheila A. .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (03) :371-377
[25]   Comparative effectiveness of glucagon-like peptide-1 receptor agonists versus dipeptidyl peptidase-4 inhibitors on noninvasive indices of hepatic steatosis and fibrosis in patients with type 2 diabetes mellitus [J].
Makri, Evangelia ;
Kita, Marina ;
Goulas, Antonis ;
Papaioannidou, Paraskevi ;
Efstathiadou, Zoe A. ;
Adamidou, Fotini ;
Polyzos, Stergios A. .
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2020, 14 (06) :1913-1919
[26]   Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: A population-based cohort study [J].
Bea, Sungho ;
Son, Heejun ;
Bae, Jae Hyun ;
Cho, Sun Wook ;
Shin, Ju-Young ;
Cho, Young Min .
DIABETES OBESITY & METABOLISM, 2024, 26 (01) :108-117
[27]   Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide [J].
Karhust, Martin L. ;
Bronden, Andreas ;
Roder, Michael E. ;
Leotta, Salvatore ;
Sonnet, David P. ;
Knop, Filip K. .
GASTROENTEROLOGY, 2019, 157 (02) :569-571
[28]   Combination therapy with once-weekly glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a case series [J].
Lajthia, Estela ;
Bucheit, John D. ;
Nadpara, Pramit A. ;
Dixon, Dave L. ;
Caldas, Lauren M. ;
Murchie, Michael ;
Sisson, Evan M. .
PHARMACY PRACTICE-GRANADA, 2019, 17 (04)
[29]   Sleep is increased by liraglutide, a glucagon-like peptide-1 receptor agonist, in rats [J].
Fang, Jidong ;
Miller, Patti ;
Grigson, Patricia S. .
BRAIN RESEARCH BULLETIN, 2023, 192 :142-155
[30]   Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes [J].
Ogawa, Susumu ;
Ishiki, Mikihito ;
Nako, Kazuhiro ;
Okamura, Masashi ;
Senda, Miho ;
Mori, Takefumi ;
Ito, Sadayoshi .
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 223 (02) :133-135